Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (21-30 of 147) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2015
Tumor-infiltrating dendritic cells in cancer pathogenesisJo Marie Tran Janco, Purushottam Lamichhane, Lavakumar Karyampudi, et al.
Seminars in Cancer Biology|July 31, 2007
Tumor immunoediting and immunosculpting pathways to cancer progressionJennifer M Reiman, Maciej Kmieciak, Masoud H Manjili, et al.
European Journal of Immunology|February 17, 2007
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responsesMaciej Kmieciak, Keith L Knutson, Catherine I Dumur, et al.
Hematology/Oncology Clinics of North America|September 10, 2003
Immunologic principles and immunotherapeutic approaches in ovarian cancerKeith L Knutson, Tyler J Curiel, Lupe Salazar, et al.
Immunobiology|June 5, 2003
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigensMary L Disis, Faith M Shiota, Douglas G McNeel, et al.
Molecular Cancer Therapeutics|January 25, 2006
Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusionHongtao Zhang, Keith L Knutson, Karl Erik Hellstrom, et al.
Plos One|November 2, 2017
Downregulation of TAP1 and TAP2 in early stage breast cancerAndrea M Henle, Aziza Nassar, Danell Puglisi-Knutson, et al.
Expert Opinion on Biological Therapy|January 5, 2002
Adoptive T-cell therapy for the treatment of solid tumoursKeith L Knutson, Bond Almand, David A Mankoff, et al.
Cancer Research|February 7, 2007
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumorsPilar Nava-Parada, Guido Forni, Keith L Knutson, et al.
Pageof 15

Showing results (21-30 of 147) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunityKeith L Knutson, Kathy Schiffman, Martin A Cheever, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2015
Tumor-infiltrating dendritic cells in cancer pathogenesisJo Marie Tran Janco, Purushottam Lamichhane, Lavakumar Karyampudi, et al.
Seminars in Cancer Biology|July 31, 2007
Tumor immunoediting and immunosculpting pathways to cancer progressionJennifer M Reiman, Maciej Kmieciak, Masoud H Manjili, et al.
European Journal of Immunology|February 17, 2007
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responsesMaciej Kmieciak, Keith L Knutson, Catherine I Dumur, et al.
Hematology/Oncology Clinics of North America|September 10, 2003
Immunologic principles and immunotherapeutic approaches in ovarian cancerKeith L Knutson, Tyler J Curiel, Lupe Salazar, et al.
Immunobiology|June 5, 2003
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigensMary L Disis, Faith M Shiota, Douglas G McNeel, et al.
Molecular Cancer Therapeutics|January 25, 2006
Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusionHongtao Zhang, Keith L Knutson, Karl Erik Hellstrom, et al.
Plos One|November 2, 2017
Downregulation of TAP1 and TAP2 in early stage breast cancerAndrea M Henle, Aziza Nassar, Danell Puglisi-Knutson, et al.
Expert Opinion on Biological Therapy|January 5, 2002
Adoptive T-cell therapy for the treatment of solid tumoursKeith L Knutson, Bond Almand, David A Mankoff, et al.
Cancer Research|February 7, 2007
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumorsPilar Nava-Parada, Guido Forni, Keith L Knutson, et al.
Pageof 15